Application of urinary hepcidin-25 determination in the early-stage diagnosis of iron deficient syndrome among children

doi:10.3969/j.issn.1673-8640.2015.08.001

Abstract

Abstract:

Objective To study the diagnostic performance of urinary hepcidin-25 for the early-stage diagnosis of iron deficient syndrome (IDS) among children. Methods By enzyme-linked immunosorbent assay (ELISA), urinary hepcidin-25 levels were determined in 25 cases of iron depletion(ID) stage, 25 cases of iron deficient erythropoiesis(IDE) stage, 25 cases of iron deficient anemia(IDA) and 25 healthy children (control group). The cut-off values of urinary hepcidin-25 for ID, IDE and IDA and corresponding diagnostic performance were analyzed by receiver operating characteristic(ROC) curve. Results There was statistical significance of urinary hepcidin-25 levels in comparison between any 2 groups of ID, IDE, IDA and control groups (P<0.05). The areas under ROC curves for urinary hepcidin-25 for differentiating ID, IDE and IDA groups from control group were 0.865, 0.974 and 0.998, respectively. The areas under ROC curves for urinary hepcidin-25 for differentiating IDE from IDA, differentiating IDE from ID, differentiating IDE from the mixing group of control with ID were 0.872, 0.870 and 0.922, respectively. Conclusions The determination of urinary hepcidin-25 level is a simple and non-invasive test, and it might have application significance in the early-stage diagnosis of IDS among children.

Key words: Hepcidin-25, Iron deficiency, Diagnostic determination, Performance

CLC Number:

R446.1

XU Shuangqing, ZOU Xiaofeng, MA Guoxiang, XU Keqian. Application of urinary hepcidin-25 determination in the early-stage diagnosis of iron deficient syndrome among children[J]. Laboratory Medicine, 2015, 30(8): 777-781.

Figures/Tables 3

References 9

[1]	ZHU A,KANESHIRO M,KAUNITZ JD.Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective[J]. Dig Dis Sci,2010,55(3): 548-559.
[2]	KAZAL LA JR.Prevention of iron deficiency in infants and toddlers[J]. Am Fam Physician,2002,66(7): 1217-1224.
[3]	COOK JD.Diagnosis and management of iron-deficiency anaemia[J]. Best Pract Res Clin Haematol,2005,18(2): 319-332.
[4]	GANZ T.Hepcidin and its role in regulating systemic iron metabolism[J]. Hematology Am Soc Hematol Educ Program,2006,1: 29-35.
[5]	张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:6-9.
[6]	CHERIAN S,FORBES DA,COOK AG,et al.An insight into the relationships between hepcidin, anemia, infections and inflammatory cytokines in pediatric refugees: a cross-sectional study[J]. PLoS ONE,2008,3(12): e4030.
[7]	NEMETH E,TUTTLE MS,POWELSON J,et al.Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization[J]. Science,2011,306(5704): 2090-2093.
[8]	BEUTLER E,FAIRBANK VF.Iron metabolism[M]. New York: McGraw-Hill,2006: 295-305.
[9]	葛青玮,刘家应,高原,等. 血清可溶性转铁蛋白受体在儿童铁缺乏中的应用[J]. 检验医学,2004,19(3): 197-199.

组别	例数	年龄(岁)	性别(例)		体重(kg)	Hb(g/L)
组别	例数	年龄(岁)	男性		体重(kg)	女性
正常对照组	25	5.1±1.3	12	13	17.1±2.7	122.0±7.3
ID组	25	5.0±1.3	11	14	17.0±2.6	119.0±4.6
IDE组	25	4.9±1.2	11	14	17.0±2.4	118.0±4.8
IDA组	25	5.0±1.3	12	13	17.3±2.4	85.0±12.4^*#△
P值		>0.05	>0.05	>0.05	>0.05	<0.05
组别	例数	HCT(%)	MCV(fL)	MCHC (g/L)	血清铁 (μmol/L)	TIBC (μmol/L)
正常对照组	25	37.0±2.1	90.5±5.0	34.3±2.2	14.6±4.0	54.0±6.5
ID组	25	35.5±2.2	88.1±5.2	34.0±2.4	12.1±3.9	56.6±7.0
IDE组	25	35.2±2.3	87.1±5.3	33.3±2.1	4.1±0.7^*#	59.1±6.6^*#
IDA组	25	23.8±2.8^*#△	70.1±6.1^*#△	26.4±2.3^*#△	3.1±1.0^*#△	100.0±12.2^*#△
P值		<0.05	<0.05	<0.05	<0.05	<0.05
组别	例数	Tsat(%)	转铁蛋白 (g/L)	铁蛋白 (ng/mL)	尿Cr (mmol/L)	尿hepcidin-25 (μg/mmol Cr)
正常对照组	25	35.8±2.0	3.0±0.4	35.4±9.2	0.291±0.042	2.6±1.4
ID组	25	35.4±2.0	3.3±0.4	9.6±1.7^*	0.304±0.047	1.1±0.4^*
IDE组	25	15.1±2.1^*#	3.5±0.4	7.0±1.4^*#	0.311±0.043	0.6±0.3^*#
IDA组	25	5.4±1.9^*#△	6.5±1.2^*#△	4.8±1.0^*#△	0.283±0.056	0.3±0.2^*#△
P值		<0.05	<0.05	<0.05	>0.05	<0.01

组别	例数	年龄(岁)	性别(例)		体重(kg)	Hb(g/L)
组别	例数	年龄(岁)	男性		体重(kg)	女性
正常对照组	25	5.1±1.3	12	13	17.1±2.7	122.0±7.3
ID组	25	5.0±1.3	11	14	17.0±2.6	119.0±4.6
IDE组	25	4.9±1.2	11	14	17.0±2.4	118.0±4.8
IDA组	25	5.0±1.3	12	13	17.3±2.4	85.0±12.4^*#△
P值		>0.05	>0.05	>0.05	>0.05	<0.05
组别	例数	HCT(%)	MCV(fL)	MCHC (g/L)	血清铁 (μmol/L)	TIBC (μmol/L)
正常对照组	25	37.0±2.1	90.5±5.0	34.3±2.2	14.6±4.0	54.0±6.5
ID组	25	35.5±2.2	88.1±5.2	34.0±2.4	12.1±3.9	56.6±7.0
IDE组	25	35.2±2.3	87.1±5.3	33.3±2.1	4.1±0.7^*#	59.1±6.6^*#
IDA组	25	23.8±2.8^*#△	70.1±6.1^*#△	26.4±2.3^*#△	3.1±1.0^*#△	100.0±12.2^*#△
P值		<0.05	<0.05	<0.05	<0.05	<0.05
组别	例数	Tsat(%)	转铁蛋白 (g/L)	铁蛋白 (ng/mL)	尿Cr (mmol/L)	尿hepcidin-25 (μg/mmol Cr)
正常对照组	25	35.8±2.0	3.0±0.4	35.4±9.2	0.291±0.042	2.6±1.4
ID组	25	35.4±2.0	3.3±0.4	9.6±1.7^*	0.304±0.047	1.1±0.4^*
IDE组	25	15.1±2.1^*#	3.5±0.4	7.0±1.4^*#	0.311±0.043	0.6±0.3^*#
IDA组	25	5.4±1.9^*#△	6.5±1.2^*#△	4.8±1.0^*#△	0.283±0.056	0.3±0.2^*#△
P值		<0.05	<0.05	<0.05	>0.05	<0.01

组间鉴别	ROC曲线下面积	P值	临界点(μg/mmol Cr)	敏感性(%)	特异性(%)
从正常对照组中鉴别出ID	0.865	0.001	<2.05	96.0	60.0
从正常对照组中鉴别出IDE	0.974	0.001	<1.25	96.0	88.0
从正常对照组中鉴别出IDA	0.998	0.001	<1.20	99.9	88.0
从IDE中鉴别出IDA	0.872	0.001	<0.42	82.0	74.0
从ID中鉴别出IDE	0.870	0.001	<0.70	70.0	95.0
从正常对照及ID混合组中鉴别出IDE	0.922	0.001	<1.30	98.0	57.0

组间鉴别	ROC曲线下面积	P值	临界点(μg/mmol Cr)	敏感性(%)	特异性(%)
从正常对照组中鉴别出ID	0.865	0.001	<2.05	96.0	60.0
从正常对照组中鉴别出IDE	0.974	0.001	<1.25	96.0	88.0
从正常对照组中鉴别出IDA	0.998	0.001	<1.20	99.9	88.0
从IDE中鉴别出IDA	0.872	0.001	<0.42	82.0	74.0
从ID中鉴别出IDE	0.870	0.001	<0.70	70.0	95.0
从正常对照及ID混合组中鉴别出IDE	0.922	0.001	<1.30	98.0	57.0

[1]	WANG Wei, ZHANG Zhixin, ZHANG Chuanbao, ZHOU Weiyan, WANG Zhiguo. Establishment of allowable total error，allowable imprecision and allowable bias for 22 endocrine analytes [J]. Laboratory Medicine, 2023, 38(8): 707-712.
[2]	TAN Chunyan, ZHOU Ying, MO Zhijiang. Errors in Appendix B examples of WS/T 505—2017 and correction [J]. Laboratory Medicine, 2023, 38(6): 569-573.
[3]	LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453.
[4]	XU Weixin, CHEN Qing, DU Wenyong, GAO Yan. Plasma metabolic markers in patients with insomnia disorder [J]. Laboratory Medicine, 2023, 38(5): 454-459.
[5]	YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222.
[6]	WANG Yajie, ZU Bailing, GAN Chenxin, WU Jiaoxiang, SHU Jie, HANG Chen, CHEN Minghui, LIN Fujun, HU Zhigang, HUANG Biao, SHENG Huiming. Identification of plasma differential peptids in PLA2R1-related membranous nephropathy patients [J]. Laboratory Medicine, 2023, 38(3): 223-229.
[7]	ZENG Yanfen, WU Quanming, ZHOU Huan, ZHANG Qiuqin, KANG Yanli, LI Yao, CHEN Xijun, HUANG Jiangang, CHEN Falin. Determination limits of a severe acute respiratory syndrome coronavirus 2 nucleic acid determination reagent in 4 determination systems [J]. Laboratory Medicine, 2023, 38(3): 261-266.
[8]	HUANG Zhongqiang, DAI Di, HOU Tieying, LIN Faquan, LU Zhiming, LIU Xiaoqi, SHEN Minna, WU Jie, ZHANG Pingan, ZHOU Jun, XIAO Yanqun, WANG Hualiang. Multicenter performance evaluation of a 7-microRNA test kit [J]. Laboratory Medicine, 2023, 38(11): 1075-1081.
[9]	MIAO Yingbo, ZHAO Qiang, SONG Ying, ZHU Peichao, ZHOU Wei, XU Chong. Research on performance specification of thrombelastogram [J]. Laboratory Medicine, 2022, 37(7): 680-683.
[10]	ZHU Yuqing, WANG Haibin, WANG Lianming, ZHAO Fang, FENG Pinning, ZHANG Peng, GUO Shuren, PENG Yibing, CHENG Liming, CHUAN Liangmin, WANG Hualiang. A multi-center evaluation of a domestic glutathione reductase determination kit [J]. Laboratory Medicine, 2022, 37(5): 449-455.
[11]	TANG Ningbo, LIU Guancai, LIU Xiaoyu, YANG Fengfan, GONG Zhimei, SUN Keqi. Establishment and evaluation for the determination of serum digitoxin as a candidate reference method [J]. Laboratory Medicine, 2022, 37(5): 456-462.
[12]	OU Tong, ZHANG Bing, ZHANG Xiuming. Re-understanding about the rational application of clinical laboratory determination technologies for COVID-19 diagnosis [J]. Laboratory Medicine, 2022, 37(4): 303-308.
[13]	LU Youli, YANG Shuangshuang, ZHANG Meiwei, OU Meixian, DONG Chunxia, SHEN Weiwei, JIANG Fengli, LI Shuijun. Simultaneous determination of 5 steroid hormones in human serum by ultra-performance liquid chromatography-tandem mass spectrometry and establishment of reference intervals in healthy adults [J]. Laboratory Medicine, 2022, 37(2): 165-173.
[14]	ZHAO Xiaomin, JIANG Xiaoyu, SHAN Kaili, SHAN Tieying, LIU Xiuzhen. Roles of Flt-3L，TF and 25（OH）D in iron deficiency anemia among infants and children [J]. Laboratory Medicine, 2022, 37(11): 1039-1043.
[15]	LIU Congcong, LI Jiaping, ZHOU Hongwei. Performance evaluation of 2 mass spectrometry systems in clinical microbial identification [J]. Laboratory Medicine, 2022, 37(11): 1084-1088.